Alluvi Retatrutide 40mg Pen

Alluvi Retatrutide 40mg Pen is a high-strength triple-agonist research compound developed for advanced metabolic, appetite-regulation, and energy-balance studies. Delivered in a precision pen format, this formulation supports consistent dosing and reliable performance across research protocols.

Retatrutide is known for its ability to activate GLP-1, GIP, and glucagon receptors simultaneously, offering broader metabolic modulation compared to traditional GLP-1 compounds.

Key Features for Alluvi Retatrutide 40mg Pen:

• 40mg retatrutide formulation

• Triple-agonist metabolic activity

• Pen-based delivery for dosing accuracy

• Designed for advanced research models

• Laboratory-grade quality standards

How It Works

This compound influences appetite signaling, insulin sensitivity, and energy expenditure by engaging multiple metabolic receptors in parallel, supporting comprehensive metabolic research.

Research Applications

Used in:

• Advanced metabolic investigations

• Appetite and satiety research

• Energy balance and fat utilisation studies

• Comparative GLP-1 pathway research

Pen-Based Advantage

The pen delivery system reduces handling errors and improves repeatability across long-term research designs.

Storage & Quality

Store refrigerated, protect from light, and do not freeze. Intended strictly for research use.